


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-9 (Canceled)

Claim 10 (Currently Amended): A method of treating a condition mediated by modulation of the thrombin receptor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a the compound of Claim 1, represented by the general formula (1):



wherein A<sub>1</sub> is an amino acid residue selected from the group consisting of cyclohexylalanine, Leu, Ile, Arg, Lys, Phe, substituted Phe, Tyr and Trp;

A<sub>2</sub> is an amino acid residue selected from the group consisting of Lys, Orn, Arg, and homo Arg;

A<sub>3</sub> is an amino acid residue selected from the group consisting of Phe, substituted Phe, homo Phe, Tyr, Trp, phenylglycine, 2-thienylalanine, 3-thienylalanine, cyclohexylalanine, Leu, Ile, Asn, Gln, Arg, homo Arg, Orn and Lys;

X is selected from the group consisting of CO, CS, and SO<sub>2</sub>;

Y is selected from the group consisting of aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, heteroarylethynyl, substituted heteroarylethynyl, arylacrylamidoheteroaryl, substituted arylacrylamidoheteroaryl, heteroarylacrylamidoheteroaryl and substituted heteroarylacrylamidoheteroaryl, provided that Y is not pyrrolidinyl, phenyl or 2-aminophenyl;

Z is selected from the group consisting of NH<sub>2</sub>, NH-alkyl, NH-aralkyl, and Arg-NH<sub>2</sub>;  
and

wherein all amino acids are of the L configuration;

and any pharmaceutically acceptable salt thereof

Claim 11 (Currently Amended): The method of Claim 10, wherein the condition is selected from the group consisting of wound healing, tissue repair, myocardial infarction, stroke, restenosis, angina, atherosclerosis, ischemic attacks, inflammation, cancer, osteoporosis, and or neurodegenerative disorders.

Claim 12 (Original): The method of Claim 11, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

Claim 13 (Original): The method of Claim 12, wherein the therapeutically effective amount of the compound is about 1 to about 50 mg/kg/day.

Claim 14 (Currently Amended): A method of treating a condition modulated by the thrombin receptor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 7 10 and a pharmaceutically acceptable carrier.

Claim 15 (Currently Amended): The method of Claim 14, wherein the condition is selected from the group consisting of wound healing, tissue repair, myocardial infarction, stroke, restenosis, angina, atherosclerosis, ischemic attacks, inflammation, cancer, osteoporosis, and ~~or~~ neurodegenerative disorders.

Claim 16 (Original): The method of Claim 14, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

Claim 17 (Original): The method of Claim 16, wherein the therapeutically effective amount of the compound is about 1 to about 50 mg/kg/day.